Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 2;33(4):1720-1734.
doi: 10.1016/j.ymthe.2025.02.037. Epub 2025 Feb 28.

A universal viral capsid protein based one step RNA synthesis and packaging system for rapid and efficient mRNA vaccine development

Jiayue Su  1 , Jinsong Zhang  1 , Xiangning Feng  1 , Jinsong Liu  1 , Shan Gao  1 , Xinrui Liu  1 , Mingwei Yang  1 , Zeliang Chen  2
Affiliations

A universal viral capsid protein based one step RNA synthesis and packaging system for rapid and efficient mRNA vaccine development

Jiayue Su et al. Mol Ther. .

Abstract

The success of coronavirus disease 2019 mRNA vaccines highlights the transformative potential of mRNA technology. Current mRNA vaccine development involves complex steps, including plasmid construction, RNA transcription, 5' capping, poly(A) tailing, and lipid nanoparticle encapsulation, yet challenges in vaccine accessibility persist. Here, we present an innovative mRNA platform leveraging the self-assembly capabilities of the MS2 bacteriophage viral capsid protein (VCP). A dual-promoter plasmid has been designed where one promoter drives VCP expression while the other transcribes target RNA containing pac sites, enabling rapid mRNA self-assembly in Escherichia coli. Using an ovalbumin (OVA)-based tumor model, we validate the efficacy of this system. Tumor growth is significantly inhibited, accompanied by robust immune activation. Flow cytometry analyses reveal increased frequencies of OVA-specific CD8+, as well as activated and memory T cells. Additionally, the MS2-OVA vaccine favorably modulated the tumor immunosuppressive microenvironment by reducing myeloid-derived suppressor cells, while sustained antibody responses demonstrated the platform's ability to induce durable humoral immunity. These findings establish the feasibility of one-step mRNA synthesis and packaging in E. coli, providing a versatile and rapid platform for mRNA vaccine development, with broad implications for addressing global vaccination challenges.

Keywords: MS2 bacteriophage capsid proteins; T cell-mediated immunity; dual-promoter system; mRNA delivery.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no conflict of interest.

References

    1. Jain S., Venkataraman A., Wechsler M.E., Peppas N.A. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv. Drug Deliv. Rev. 2021;179 doi: 10.1016/j.addr.2021.114000. - DOI - PMC - PubMed
    1. Andersen T.K., Bodin J., Oftung F., Bogen B., Mjaaland S., Grødeland G. Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.747032. - DOI - PMC - PubMed
    1. Son S., Nam J., Zenkov I., Ochyl L.J., Xu Y., Scheetz L., Shi J., Farokhzad O.C., Moon J.J. Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination. Nano Lett. 2020;20:1499–1509. doi: 10.1021/acs.nanolett.9b03483. - DOI - PMC - PubMed
    1. Chen J., Ye Z., Huang C., Qiu M., Song D., Li Y., Xu Q. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc. Natl. Acad. Sci. USA. 2022;119 doi: 10.1073/pnas.2207841119. - DOI - PMC - PubMed
    1. Fotoran W.L., Silva J.R.D., Glitz C., Ferreira L.C.d.S., Wunderlich G. Establishment of an Antiplasmodial Vaccine Based on PfRH5-Encoding RNA Replicons Stabilized by Cationic Liposomes. Pharmaceutics. 2023;15 doi: 10.3390/pharmaceutics15041223. - DOI - PMC - PubMed

LinkOut - more resources